Abstract:Immunotherapies such as CAR-T cell transfer and antibody-targeted therapy have produced promising clinical outcomes in patients with advanced and metastatic cancer that are resistant to conventional therapies. However, with increasing use of cancer immunotherapy in clinical treatment, multiple therapy-resistance mechanisms have gradually emerged. The tumor microenvironment (TME), an integral component of cancer, can significantly influence the therapeutic response. Thus, it is worth exploring the potential of TME in modulating therapy resistance, in the hope to devise novel strategies to reinforcing anti-cancer treatments such as immunotherapy. As a crucial recycling process in the complex TME, the role of autophagy in tumor immunity has been increasingly appreciated. Firstly, autophagy in tumor cells can affect their immune response through modulating MHC-I-antigen complexes, thus modulating immunogenic tumor cell death, changing functions of immune cells via secretory autophagy, reducing the NK- and CTL-mediated cell lysis and degradation of immune checkpoint proteins. Secondly, autophagy is critical for the differentiation, maturation and survival of immune cells in the TME and can significantly affect the immune function of these cells, thereby regulating the anti-tumor immune response. Thirdly, alteration of autophagic activity in stromal cells, especially in fibroblasts, can reconstruct the three-dimensional stromal environment and metabolic reprogramming in the TME. A number of studies have demonstrated that optimal induction or inhibition of autophagy may lead to effective therapeutic regimens when combined with immunotherapy. This review discusses the important roles of autophagy in tumor cells, immune cells and stromal cells in the context of tumor immunity, and the potential of combining the autophagy-based therapy with immunotherapy as novel therapeutic approaches against cancer.

Targeted Mevalonate Pathway and Autophagy in Antitumor Immunotherapy

Research Progress on Mitochondria Regulating Tumor Immunity.

Targeting metabolism to enhance immunotherapy within tumor microenvironment

Metabolic interventions: A new insight into the cancer immunotherapy

Tumor Metabolic Crosstalk and Immunotherapy

Exploring the Emerging Role of the Gut Microbiota and Tumor Microenvironment in Cancer Immunotherapy

Association between Metabolic Reprogramming and Immune Regulation in Digestive Tract Tumors

Metabolic reprogramming, autophagy, and ferroptosis: Novel arsenals to overcome immunotherapy resistance in gastrointestinal cancer

Metabolic gatekeepers: harnessing tumor-derived metabolites to optimize T cell-based immunotherapy efficacy in the tumor microenvironment

Tumor Metabolism-Rewriting Nanomedicines for Cancer Immunotherapy.

Targeting lipid metabolism reprogramming of immunocytes in response to the tumor microenvironment stressor: A potential approach for tumor therapy

Mitochondria in tumor immune surveillance and tumor therapies targeting mitochondria

Metabolic Modifications, Inflammation, and Cancer Immunotherapy

Mitochondrial Immune Regulation and Anti-Tumor Immunotherapy Strategies Targeting Mitochondria

Emerging role of autophagy in anti-tumor immunity: Implications for the modulation of immunotherapy resistance

Targeting T Cell Metabolism in the Tumor Microenvironment: an Anti-Cancer Therapeutic Strategy

Metabolic reprogramming in tumor immune microenvironment: Impact on immune cell function and therapeutic implications

Metabolic Interplay in the Tumor Microenvironment: Implications for Immune Function and Anticancer Response

Targeting Tumor Metabolism: A New Challenge to Improve Immunotherapy

Metabolic reprograming of MDSCs within tumor microenvironment and targeting for cancer immunotherapy